Saturday 17 October 2026
Export MDWD’s income statement to Excel — free account
MediWound Ltd.
MDWD Healthcare Biotechnology
MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.85
0.36
−2.95%
Follow MDWD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 5 | 4 | 3 |
| 0.00% | (63.49%) | 0.00% | (75.42%) | ||
| (24.36%) | (29.90%) | (35.04%) | (29.06%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (6,551.77%) | |
Return on Tangible Assets |
(34.34%) | (45.14%) | (51.40%) | (44.09%) | |
Average Days of Receivables |
105.29 | 58.78 | 69.27 | 107.47 | |
Free Cash Flow per Share |
(1.69) | (1.90) | (1.95) | (2.21) | |
Free Cash Flow |
(18.60) | (21.63) | (25.13) | (28.53) | |
Capital Expenditures |
(3.86) | (5.50) | (6.37) | (6.39) | |
| Other line items | |||||
Cash ROIC |
(16.86%) | (22.15%) | (28.89%) | (40.19%) | |
Accounts Receivable Turnover |
3.69 | 3.75 | 3.65 | 2.31 | |
Accounts Payable Turnover |
2.93 | 2.12 | 1.88 | 1.49 | |
Inventory Turnover |
4.59 | 4.04 | 2.79 | 2.52 | |
Average Days of Payables |
182.15 | 203.69 | 232.30 | 277.54 | |
Days of Inventory on Hand |
94.28 | 109.01 | 149.64 | 149.84 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
61.28% | 84.44% | 114.78% | 160.41% | |
Selling, General and Administrative Expense of Revenue |
69.73% | 83.81% | 101.51% | 126.65% | |
Share Based Compensation of Revenue |
15.61% | 18.33% | 20.08% | 23.61% | |
Interest Coverage |
— | (1.65) | — | (2.27) | |
Operating CF/Net income |
0.72 | 0.68 | 0.72 | 1.10 | |
Depreciation/Fixed assets |
0.09 | 0.10 | 0.09 | 0.09 | |
Capex/Depreciation |
(2.46) | (2.96) | (3.39) | (3.39) | |
Revenue per Share |
1.90 | 1.49 | 1.12 | 0.92 | |
Operating CF per Share |
(1.34) | (1.42) | (1.46) | (1.72) | |
Capex per Share |
(0.35) | (0.48) | (0.49) | (0.50) | |
Capex to Sales |
0.18 | 0.32 | 0.44 | 0.54 |
Columns are period end dates